Literature DB >> 27193793

Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas.

Eric C Ehman1, Spencer C Behr2, Sarah E Umetsu3, Nicholas Fidelman2, Ben M Yeh4, Linda D Ferrell5, Thomas A Hope6.   

Abstract

PURPOSE: To compare frequency and inter-reader agreement for LI-RADS v2014 major features at CT vs. MRI in pathology-proven cases of hepatocellular carcinoma.
METHODS: Pathology reports and imaging studies from patients having undergone liver transplant or hepatectomy for hepatocellular carcinoma were reviewed. Size, location, washout, and capsule appearance for each lesion were recorded by two radiologists. Cohen's kappa and intraclass correlation coefficients (ICC) were calculated.
RESULTS: One hundred and thirty-four patients with 184 tumors were reviewed. Seventy-seven percentage of lesions were imaged by CT and 23% by MRI. No lesions were evaluated with both modalities. Mean lesion diameter was 2.6 ± 1.3 cm (ICC = 0.92). Arterial phase hyperenhancement was seen in 86% of lesions (κ = 0.75). Washout was seen in 82% of studies (κ = 0.61). Arterial phase hyperenhancement and washout were seen equally at CT and MRI (p = 1.00 and 0.46, respectively). Capsule was infrequently observed (27%) but was seen more commonly at MRI (44%) than at CT (17%) with p = 0.002 and (κ = 0.56). Forty-seven percent of lesions with at least one prior study met LI-RADS criteria for threshold growth. The rates of LI-RADS categories 3, 4, and 5 were 9%, 37%, and 54%, respectively. More 1-2 cm LI-RADS 5 lesions were seen at MRI (43%) than at CT (8%), p = 0.01.
CONCLUSION: A combined LI-RADS 4/5 group was 91% sensitive for hepatocellular carcinoma. Arterial enhancement and washout were seen more frequently than capsule, the sole finding seen more frequently at MRI than at CT. Inter-reader reliability was substantial for arterial hyperenhancement and washout but moderate for capsule. Capsule remains an important finding in small arterially enhancing lesions (1-2 cm) which require a second major criterion to upgrade to a LI-RADS 5 lesion.

Entities:  

Keywords:  CT; Hepatocellular carcinoma; LI-RADS; MRI

Mesh:

Substances:

Year:  2016        PMID: 27193793      PMCID: PMC5292939          DOI: 10.1007/s00261-015-0623-5

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  23 in total

1.  Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging.

Authors:  Matthew S Davenport; Shokoufeh Khalatbari; Peter S C Liu; Katherine E Maturen; Ravi K Kaza; Ashish P Wasnik; Mahmoud M Al-Hawary; Daniel I Glazer; Erica B Stein; Jeet Patel; Deepak K Somashekar; Benjamin L Viglianti; Hero K Hussain
Journal:  Radiology       Date:  2014-02-18       Impact factor: 11.105

2.  Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma.

Authors:  Young Kon Kim; Chong Soo Kim; Gyong Ho Chung; Young-Min Han; Sang Yong Lee; Su Bin Chon; Jeong Min Lee
Journal:  AJR Am J Roentgenol       Date:  2006-01       Impact factor: 3.959

3.  Hepatocellular carcinoma likelihood on MRI exams: evaluation of a standardized categorization system.

Authors:  Nicholas Petruzzi; Donald Mitchell; Flavius Guglielmo; Patrick O'Kane; Sandeep Deshmukh; Christopher Roth; Conor Shortt; Stephen Balfour; Laurence Parker
Journal:  Acad Radiol       Date:  2013-03-28       Impact factor: 3.173

4.  Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

Authors:  Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Osamu Matsui; Michiie Sakamoto; Osamu Nakashima; Masamichi Kojiro; Masatoshi Makuuchi
Journal:  Dig Dis       Date:  2011-08-09       Impact factor: 2.404

5.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

6.  Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic livers: accuracy of helical CT in transplant patients.

Authors:  J H Lim; C K Kim; W J Lee; C K Park; K C Koh; S W Paik; J W Joh
Journal:  AJR Am J Roentgenol       Date:  2000-09       Impact factor: 3.959

7.  The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis.

Authors:  Angelo Sangiovanni; Matteo A Manini; Massimo Iavarone; Raffaella Romeo; Laura V Forzenigo; Mirella Fraquelli; Sara Massironi; Cristina Della Corte; Guido Ronchi; Maria Grazia Rumi; Piero Biondetti; Massimo Colombo
Journal:  Gut       Date:  2009-12-01       Impact factor: 23.059

8.  Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.

Authors:  George N Ioannou; James D Perkins; Robert L Carithers
Journal:  Gastroenterology       Date:  2008-02-13       Impact factor: 22.682

9.  Liver transplantation for hepatocellular carcinoma: the MELD impact.

Authors:  Pratima Sharma; Vijayan Balan; Jose L Hernandez; Ann M Harper; Erick B Edwards; Hector Rodriguez-Luna; Thomas Byrne; Hugo E Vargas; David Mulligan; Jorge Rakela; Russell H Wiesner
Journal:  Liver Transpl       Date:  2004-01       Impact factor: 5.799

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  20 in total

1.  Longitudinal evolution of CT and MRI LI-RADS v2014 category 1, 2, 3, and 4 observations.

Authors:  Cheng William Hong; Charlie C Park; Adrija Mamidipalli; Jonathan C Hooker; Soudabeh Fazeli Dehkordy; Saya Igarashi; Mohanad Alhumayed; Yuko Kono; Rohit Loomba; Tanya Wolfson; Anthony Gamst; Paul Murphy; Claude B Sirlin
Journal:  Eur Radiol       Date:  2019-02-26       Impact factor: 5.315

Review 2.  Pitfalls and problems to be solved in the diagnostic CT/MRI Liver Imaging Reporting and Data System (LI-RADS).

Authors:  Yeun-Yoon Kim; Jin-Young Choi; Claude B Sirlin; Chansik An; Myeong-Jin Kim
Journal:  Eur Radiol       Date:  2018-08-16       Impact factor: 5.315

3.  Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS.

Authors:  Barbara Schellhaas; Matthias Hammon; Deike Strobel; Lukas Pfeifer; Christian Kielisch; Ruediger S Goertz; Alexander Cavallaro; Rolf Janka; Markus F Neurath; Michael Uder; Hannes Seuss
Journal:  Eur Radiol       Date:  2018-04-19       Impact factor: 5.315

4.  Gadoxetic acid-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: can hypointensity on the late portal venous phase be used as an alternative to washout?

Authors:  Kyoung A Baek; Seung Soo Kim; Hyeong Cheol Shin; Jeong Ah Hwang; Seo-Youn Choi; Woong Hee Lee; Chan Ho Park; Hyoung Nam Lee; Nam Hun Heo
Journal:  Abdom Radiol (NY)       Date:  2020-09

5.  Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.

Authors:  Daniel R Ludwig; Tyler J Fraum; Roberto Cannella; David H Ballard; Richard Tsai; Muhammad Naeem; Maverick LeBlanc; Amber Salter; Allan Tsung; Anup S Shetty; Amir A Borhani; Alessandro Furlan; Kathryn J Fowler
Journal:  Abdom Radiol (NY)       Date:  2019-06

6.  Deep learning for liver tumor diagnosis part II: convolutional neural network interpretation using radiologic imaging features.

Authors:  Clinton J Wang; Charlie A Hamm; Lynn J Savic; Marc Ferrante; Isabel Schobert; Todd Schlachter; MingDe Lin; Jeffrey C Weinreb; James S Duncan; Julius Chapiro; Brian Letzen
Journal:  Eur Radiol       Date:  2019-05-15       Impact factor: 5.315

7.  Change in Liver Imaging Reporting and Data System Characterization of Focal Liver Lesions Using Gadoxetate Disodium Magnetic Resonance Imaging Compared With Contrast-Enhanced Computed Tomography.

Authors:  Thomas A Hope; Rizwan Aslam; Stefanie Weinstein; Benjamin M Yeh; Carlos U Corvera; Alex Monto; Judy Yee
Journal:  J Comput Assist Tomogr       Date:  2017 May/Jun       Impact factor: 1.826

8.  Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI.

Authors:  Scott M Thompson; Ishan Garg; Eric C Ehman; Shannon P Sheedy; Candice A Bookwalter; Rickey E Carter; Lewis R Roberts; Sudhakar K Venkatesh
Journal:  Br J Radiol       Date:  2018-08-29       Impact factor: 3.039

9.  LI-RADS v2017 categorisation of HCC using CT: Does moderate to severe fatty liver affect accuracy?

Authors:  Seung Soo Kim; Jeong Ah Hwang; Hyeong Cheol Shin; Seo-Youn Choi; Tae Wook Kang; Sung Shick Jou; Woong Hee Lee; Suyeon Park; Nam Hun Heo
Journal:  Eur Radiol       Date:  2018-08-02       Impact factor: 5.315

Review 10.  Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients.

Authors:  Victoria Chernyak; Kathryn J Fowler; Aya Kamaya; Ania Z Kielar; Khaled M Elsayes; Mustafa R Bashir; Yuko Kono; Richard K Do; Donald G Mitchell; Amit G Singal; An Tang; Claude B Sirlin
Journal:  Radiology       Date:  2018-09-25       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.